FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034342182> ?p ?o ?g. }

• W3034342182 endingPage "e1639" @default.
• W3034342182 startingPage "e1628" @default.
• W3034342182 abstract "Abstract Trial Information Click here to access other published clinical trials. Lessons Learned The combination of the antivascular endothelial growth factor receptor 2 monoclonal antibody, ramucirumab, and the type II MET kinase inhibitor, merestinib, is tolerable. Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with metastatic colorectal cancer (mCRC). Further development of this combination would likely necessitate the identification of subsets of patients with mCRC where the clinical benefit is of clinical relevance. Background This study evaluated safety, preliminary efficacy, and pharmacokinetics of ramucirumab plus merestinib in patients with MCR previously treated with oxaliplatin and/or irinotecan. Methods Open-label phase Ia/b study comprising 3+3 dose-limiting toxicity (DLT) observation and expansion parts. Treatment was ramucirumab 8 mg/kg on days 1 and 15 and merestinib 80 mg once daily (QD; 28-day cycle). Primary objective was safety and tolerability. Secondary objectives were pharmacokinetics and preliminary antitumor activity. Exploratory objective was biomarker associations. Results Safety findings: DLT (proteinuria) of 7 phase Ia patients (the expansion part started at the initial recommended dose level); 16 patients (70%) with grade ≥3 treatment-emergent adverse events (TEAEs); 10 patients (43%) with grade ≥3 treatment-related TEAEs. The most common grade ≥3 treatment-related TEAEs were fatigue (4 patients [17%]) and increased blood alkaline phosphatase, diarrhea, and hypertension (2 patients each [9%]). One patient discontinued treatment because of cholestatic hepatitis. Geometric mean trough concentrations at cycle 1, day 15, were ramucirumab, 24.8 μg/mL; merestinib, 130 ng/mL. No complete or partial response was seen; 12 patients (52%) achieved stable disease. Median progression-free survival was 3.3 months (95% confidence interval [CI]: 1.6–4.4). Median overall survival was 8.9 months (95% CI: 3.5–12.7). There were no associations between genetic alterations and efficacy. Conclusion Ramucirumab plus merestinib is tolerable and may have clinical benefit in biomarker-unselected, heavily pretreated patients with mCRC." @default.
• W3034342182 created "2020-06-19" @default.
• W3034342182 creator A5004703610 @default.
• W3034342182 creator A5010668711 @default.
• W3034342182 creator A5012608968 @default.
• W3034342182 creator A5020105181 @default.
• W3034342182 creator A5025309761 @default.
• W3034342182 creator A5027371764 @default.
• W3034342182 creator A5045197829 @default.
• W3034342182 creator A5046947091 @default.
• W3034342182 creator A5055671933 @default.
• W3034342182 creator A5057178141 @default.
• W3034342182 creator A5084349853 @default.
• W3034342182 creator A5087541775 @default.
• W3034342182 creator A5090555713 @default.
• W3034342182 creator A5090682219 @default.
• W3034342182 date "2020-07-17" @default.
• W3034342182 modified "2023-09-27" @default.
• W3034342182 title "Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings" @default.
• W3034342182 cites W1997407706 @default.
• W3034342182 cites W2054633892 @default.
• W3034342182 cites W2066852162 @default.
• W3034342182 cites W2091095982 @default.
• W3034342182 cites W2096396175 @default.
• W3034342182 cites W2104759721 @default.
• W3034342182 cites W2147834058 @default.
• W3034342182 cites W2151053740 @default.
• W3034342182 cites W242040007 @default.
• W3034342182 cites W2611401373 @default.
• W3034342182 cites W2753841357 @default.
• W3034342182 cites W2781525129 @default.
• W3034342182 cites W2794052642 @default.
• W3034342182 cites W2887890964 @default.
• W3034342182 cites W2912403850 @default.
• W3034342182 cites W2919254077 @default.
• W3034342182 doi "https://doi.org/10.1634/theoncologist.2020-0520" @default.
• W3034342182 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7648328" @default.
• W3034342182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32537847" @default.
• W3034342182 hasPublicationYear "2020" @default.
• W3034342182 type Work @default.
• W3034342182 sameAs 3034342182 @default.
• W3034342182 citedByCount "3" @default.
• W3034342182 countsByYear W30343421822022 @default.
• W3034342182 crossrefType "journal-article" @default.
• W3034342182 hasAuthorship W3034342182A5004703610 @default.
• W3034342182 hasAuthorship W3034342182A5010668711 @default.
• W3034342182 hasAuthorship W3034342182A5012608968 @default.
• W3034342182 hasAuthorship W3034342182A5020105181 @default.
• W3034342182 hasAuthorship W3034342182A5025309761 @default.
• W3034342182 hasAuthorship W3034342182A5027371764 @default.
• W3034342182 hasAuthorship W3034342182A5045197829 @default.
• W3034342182 hasAuthorship W3034342182A5046947091 @default.
• W3034342182 hasAuthorship W3034342182A5055671933 @default.
• W3034342182 hasAuthorship W3034342182A5057178141 @default.
• W3034342182 hasAuthorship W3034342182A5084349853 @default.
• W3034342182 hasAuthorship W3034342182A5087541775 @default.
• W3034342182 hasAuthorship W3034342182A5090555713 @default.
• W3034342182 hasAuthorship W3034342182A5090682219 @default.
• W3034342182 hasBestOaLocation W30343421821 @default.
• W3034342182 hasConcept C112705442 @default.
• W3034342182 hasConcept C121608353 @default.
• W3034342182 hasConcept C126322002 @default.
• W3034342182 hasConcept C143998085 @default.
• W3034342182 hasConcept C197934379 @default.
• W3034342182 hasConcept C2778375690 @default.
• W3034342182 hasConcept C2779551604 @default.
• W3034342182 hasConcept C2780259306 @default.
• W3034342182 hasConcept C2780962732 @default.
• W3034342182 hasConcept C526805850 @default.
• W3034342182 hasConcept C71924100 @default.
• W3034342182 hasConcept C90924648 @default.
• W3034342182 hasConceptScore W3034342182C112705442 @default.
• W3034342182 hasConceptScore W3034342182C121608353 @default.
• W3034342182 hasConceptScore W3034342182C126322002 @default.
• W3034342182 hasConceptScore W3034342182C143998085 @default.
• W3034342182 hasConceptScore W3034342182C197934379 @default.
• W3034342182 hasConceptScore W3034342182C2778375690 @default.
• W3034342182 hasConceptScore W3034342182C2779551604 @default.
• W3034342182 hasConceptScore W3034342182C2780259306 @default.
• W3034342182 hasConceptScore W3034342182C2780962732 @default.
• W3034342182 hasConceptScore W3034342182C526805850 @default.
• W3034342182 hasConceptScore W3034342182C71924100 @default.
• W3034342182 hasConceptScore W3034342182C90924648 @default.
• W3034342182 hasIssue "11" @default.
• W3034342182 hasLocation W30343421821 @default.
• W3034342182 hasLocation W30343421822 @default.
• W3034342182 hasOpenAccess W3034342182 @default.
• W3034342182 hasPrimaryLocation W30343421821 @default.
• W3034342182 hasRelatedWork W1977793218 @default.
• W3034342182 hasRelatedWork W2037724349 @default.
• W3034342182 hasRelatedWork W2050348440 @default.
• W3034342182 hasRelatedWork W2069668461 @default.
• W3034342182 hasRelatedWork W2080692829 @default.
• W3034342182 hasRelatedWork W2086707902 @default.
• W3034342182 hasRelatedWork W2127366124 @default.
• W3034342182 hasRelatedWork W2363674970 @default.
• W3034342182 hasRelatedWork W2521675697 @default.
• W3034342182 hasRelatedWork W2577979650 @default.

• next